Is Pulse Biosciences (PLSE) Fully Valued As Its Thyroid Trial Reaches 100 Patients?

Clinical milestone reshapes attention on Pulse Biosciences

Pulse Biosciences (PLSE) has finished enrolling 100 patients in its PRECISE-BTN thyroid nodule study and has reached a full 12 month follow up for the first participant in the trial.

Pulse Biosciences has seen sharp swings around this clinical update, with the share price down 1.0% over the last day but still up 5.7% across the past month. This performance is supported by a very large year to date share price return of 298.1% and a three year total shareholder return above 10x, which suggests that investors are reacting to each trial milestone as a new data point on both potential growth and risk.

Scan other fast-moving healthcare opportunities by reviewing our hand picked list of 37 healthcare AI stocks that, similar to Pulse Biosciences, are tying clinical milestones to potential market moves.

Pulse Biosciences now carries both a rapidly developing thyroid platform and a roughly US$3.8b market value. Is this still a strong business at a stretched price, or a justified premium on future proofing?

Most Popular Narrative: 18% Overvalued

Against a last close of $53.31, the most followed narrative for Pulse Biosciences pegs fair value at $45.25, implying the stock trades at a premium that hinges on ambitious execution across thyroid and cardiac programs.

Early commercial traction of the nPulse Vybrance system in benign thyroid nodule ablation, supported by growing procedure volumes and positive physician feedback, positions the company to convert existing thyroidectomy volume and unlock a large base of watchful waiting patients. This is expected to accelerate revenue growth and increase recurring disposable sales.

See why 2 investors see Pulse Biosciences as 18% overvalued.

Result: Fair Value of $45.25 (OVERVALUED)

Still, the Pulse Biosciences story leans heavily on pivotal trial outcomes and on scaling from just US$1.2m of revenue, compared with a recent annual net loss of US$80.1m.

Find out about the key risks to this Pulse Biosciences narrative.

Next Steps

If this mix of optimism and concern around Pulse Biosciences feels familiar, act while the data is fresh and form your own view with 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Pulse Biosciences?

If Pulse Biosciences has sharpened your focus on opportunity and risk, do not stop here. Broaden your watchlist now so you are not reacting late.

• Spot potential mispricings early by scanning a 30 high quality undervalued stocks. This tool filters for strong fundamentals at prices that may not fully reflect their quality.
• Strengthen portfolio resilience by reviewing a list of solid balance sheet and fundamentals (23 results). This highlights businesses with robust finances supporting long term staying power.
• Get ahead of the crowd by tracking a 17 high quality undiscovered gems focused on under-followed companies with solid numbers that many investors might be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com